GlassScriptPhysician profile
Prachi A Jain
NPI 1225569783
$1,032.59
in general payments reported to CMS, 2019-2025
15 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.69 · 2024: $187 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.64 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.87 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $196.02 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $128.79 | 2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $118.20 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Ipsen Biopharmaceuticals, INC | $84.82 | 2025 | Onivyde |
| Astrazeneca Pharmaceuticals LP | $49.53 | 2024 | Enhertu |
| Gilead Sciences, INC. | $48.25 | 2025 | Trodelvy |
| Adc Therapeutics America, INC. | $46.36 | 2025 | |
| Alexion Pharmaceuticals, INC. | $36.88 | 2025 | Ultomiris |
| Astellas Pharma US INC | $31.08 | 2025 | Vyloy |
| Regeneron Healthcare Solutions, INC. | $24.35 | 2025 | Libtayo |
| Abbvie INC. | $18.46 | 2024 | |
| Taiho Oncology, INC. | $18.06 | 2025 | |
| Lilly USA, LLC | $15.01 | 2024 | Jaypirca, Retevmo, Verzenio |
| Glaxosmithkline, LLC. | $14.91 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prachi Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.